The databook is designed to serve as a comprehensive guide to navigating this
sector. The databook focuses on market statistics denoted in the form of
revenue and y-o-y growth and CAGR across the globe and regions. A detailed
competitive and opportunity analyses related to investigational new drug cdmo market will
help companies and investors design strategic landscapes.
Small molecule was the largest segment with a revenue share of
88.84% in
2021.
Horizon Databook has segmented the Australia investigational new drug cdmo market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to
2028.
- Australia Investigational New Drug CDMO Product Outlook (Revenue, USD Million, 2018-2028)
- Small Molecule
- Large Molecule
- Australia Investigational New Drug CDMO Services Outlook (Revenue, USD Million, 2018-2028)
- Contract Development
- Small Molecule
- Bioanalysis and DMPK studies
- Toxicology Testing
- Pathology and safety pharmacology studies
- Drug substance synthetic route development
- Drug substance process development
- Form selection crystallization process development
- Scale-up of drug substance
- Preformulation
- Preclinical formulation selection
- First in Man Formulation/ Process Development
- Analytical method development / validation
- Release testing of drug substance and drug product
- Work up Purification Steps
- Telescoping & Process Refining
- Initial Optimization
- Formal stability of drug substance and drug product
- Large Molecule
- Cell Line development
- Process Development
- Upstream
- Downstream
- MABs
- Recombinant proteins
- Others
- Contract Manufacturing
- Small Molecule
- Oral Solids
- Liquid and Semi-solids
- Injectables
- Others
- Large Molecule
- MABs
- Recombinant proteins
- Others
- Australia Investigational New Drug CDMO End Use Outlook (Revenue, USD Million, 2018-2028)
- Pharmaceutical Companies
- Biotech Companies
- Others
Reasons to
subscribe to Australia investigational new drug cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of
Australia investigational new drug cdmo market databook
-
Our clientele includes a mix of investigational new drug cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed
overview of
country-level
data and insights on the Australia investigational new drug cdmo market , including
forecasts for subscribers. This
country
databook contains high-level insights into
Australia investigational new drug cdmo market from
2018 to
2028, including revenue
numbers, major trends, and company profiles.